FDA Brief

Warning letters Drugs

FDA warning letter to

Chemical Services Group, Inc./Royal Chemical Company

High riskIssued Apr 5, 2023Posted Apr 18, 2023Division of Pharmaceutical Quality Operations I

Royal Chemical Company made OTC hand sanitizer on equipment shared with industrial chemicals, and FDA found cleaning, supplier testing and quality unit failures.

What happened

FDA inspected the Royal Chemical Company drug manufacturing plant in East Stroudsburg, Pennsylvania, from October 31 to November 8, 2022, and found the company made over-the-counter hand sanitizer on equipment also used for industrial chemicals such as cleaning products, polymer production and paint additives. Investigators also found the company relied on ethanol suppliers' certificates of analysis (the supplier's own test results) without qualifying the suppliers or testing each lot itself, and that the quality unit did not carry out its duties. The company's November 22, 2022 reply to the inspection observations (Form FDA 483, the list of problems given at the end of an inspection) was inadequate, and in response to an August 31, 2022 records request the firm named more ethanol suppliers than it had identified during the inspection.

What FDA found

  1. The company made hand sanitizer on the same equipment used for industrial chemicals, and had no procedures to clean the transfer pipes and external storage tanks, which were left open to the outside.

    21 CFR 211.67(b)
  2. It accepted ethanol from unqualified suppliers on certificates of analysis alone, without testing each lot for identity, purity, strength and quality.

    21 CFR 211.84(d)(2)
  3. Ethanol lots were co-mingled in a storage tanker, and manufacturing records listed only 'bulk' with no supplier or lot number, so batches could not be traced.

    21 CFR 211.84(d)(2)
  4. Batch release testing did not include known impurities such as methanol and benzene, and acceptance criteria were not adequate to assure the product met specifications.

    21 CFR 211.165(d)
  5. The quality unit failed to oversee cleaning procedures, vendor qualification, packaging and labeling, process validation, release of drug products, and investigations into high colony counts in the water system.

    21 CFR 211.22

What FDA wants

FDA tells the company to correct the violations promptly and to reply in writing within 15 working days describing what it has done and how it will prevent recurrence; if the work is not finished, it must give reasons and a schedule. FDA also recommends engaging a qualified CGMP consultant.

Who should pay attention

  • distributors and retailers that sold this hand sanitizer
  • companies that buy hand sanitizer or other OTC drugs from contract manufacturers
  • quality teams at firms that make drugs and industrial chemicals in the same plant

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  2. Signature Formulations LLC

    FDA warns Signature Formulations about contaminated contract-manufactured drug products and cross-contamination at its Phoenix facility.

    High risk
  3. Shoolin Pharma Chem LLP

    Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.

    High risk
  4. Dabur India Limited

    FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.

    High risk